Ironwood Pharma Resolves Ferring Dispute, Amends License Terms
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ironwood Pharma ( (IRWD) ) has issued an update.
On December 18, 2025, Ironwood Pharmaceuticals’ subsidiary VectivBio AG amended its exclusive license agreement with Ferring International Center to revise financial and intellectual property terms, including a total payment obligation of $12.5 million—an initial $7.5 million followed by $5 million due by December 31, 2026, subject to possible acceleration—alongside new tiered royalty commitments on net sales of licensed products. Under the revised structure, VectivBio will pay Ferring a high single-digit royalty for seven years following first commercial sale of each licensed product and a reduced low single-digit royalty thereafter until relevant patent coverage expires, while the amendment also clarifies ownership and other IP rights; on the same date, VectivBio, Ironwood and Ferring entered into a settlement and release resolving all claims related to Ferring’s lawsuit in the U.S. District Court for the Eastern District of Texas, removing a legal overhang and providing clearer economic and IP terms around the licensed portfolio.
The most recent analyst rating on (IRWD) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.
Spark’s Take on IRWD Stock
According to Spark, TipRanks’ AI Analyst, IRWD is a Neutral.
Ironwood Pharma’s overall stock score is primarily influenced by its financial performance challenges, including negative profitability and high leverage. The technical analysis shows strong bullish momentum, but the overbought conditions could pose a risk. Valuation is moderate, with a P/E ratio of 25, but the lack of a dividend yield limits immediate income potential. Addressing financial stability issues is crucial for long-term growth.
To see Spark’s full report on IRWD stock, click here.
More about Ironwood Pharma
Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing gastrointestinal and other specialty medicines, and operates through subsidiaries including VectivBio AG to advance licensed therapeutic products in its pipeline.
Average Trading Volume: 2,373,292
Technical Sentiment Signal: Sell
Current Market Cap: $509.2M
For a thorough assessment of IRWD stock, go to TipRanks’ Stock Analysis page.
